Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453789 | 0.92 | MEN1 (0.47) | MEN1KMT2AEPHX2BPTFPKM | |
| SCHEMBL23453792 | 0.91 | MEN1 (0.49) | MEN1KMT2AEPHX2BPTFPKM | |
| SCHEMBL23453822 | 0.86 | MEN1 (0.49) | MEN1KMT2ABPTFPKMLMNA | |
| SCHEMBL23453824 | 0.85 | MEN1 (0.41) | MEN1KMT2AEPHX2LMNAALDH1A1 | |
| SCHEMBL23453829 | 0.85 | MEN1 (0.51) | MEN1KMT2ABPTFPKMLMNA | |
| SCHEMBL23453836 | 0.84 | MEN1 (0.41) | MEN1KMT2AEPHX2BPTFPKM | |
| SCHEMBL23453815 | 0.80 | EPHX2 (0.46) | MEN1KMT2AEPHX2KDM4E | |
| SCHEMBL23453860 | 0.80 | ALDH1A1 (0.43) | MEN1KMT2AEPHX2BPTFLMNA | |
| SCHEMBL23453819 | 0.77 | TP53 (0.42) | MEN1KMT2AEPHX2BPTFLMNA | |
| SCHEMBL12120111 | 0.77 | MEN1 (0.74) | MEN1KMT2AEPHX2BPTFPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169804-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2021-06-10 | — | — | US | disclosed |
| WO-2021113365-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169804-A1 | NANOMATERIALS | POLRMT, PHOSPHO1, FABP1 | MEN1 2019/4885KMT2A 2411/4885EPHX2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.